Mannatech, Inc. Hits New 52-Week Low at USD 6.16

Mannatech, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 6.16 as of March 9, 2026. This decline marks a significant downturn for the company, which has seen its stock price drop by 18.75% over the past year, contrasting sharply with the S&P 500's performance of 17.78% during the same period. The company's financial metrics reveal a challenging landscape. Mannatech's market capitalization stands at USD 19 million, and it currently operates at a loss, with a return on equity of -23.83%. The stock's price-to-book ratio is 2.79, indicating a premium over its book value. Additionally, the company has reported a net profit loss of USD 2.39 million, reflecting a staggering decline of 150.84%. Institutional investor participation has also waned, with a 10.19% decrease in stakes over the last quarter, leaving them with a collective holding of just 12.16%. This trend, coupled with a lack of dividend yield and a negative debt-equity ratio of -0.40, underscores the financial challenges facing Mannatech, Inc. as it navigates a difficult market environment.